Business UpdateOct 13, 2026, 07:31 AM
BrainsWay SWIFT TMS Coverage Expands to Over 70 Million Lives
AI Summary
BrainsWay Ltd. announced an expansion in favorable medical policies for its SWIFT Accelerated Deep TMS protocol, now covering over 70 million lives in the U.S. This growth reflects increasing acceptance and adoption of Deep TMS for conditions like major depressive disorder and obsessive-compulsive disorder. CEO Hadar Levy emphasized the strong efficacy data and growing body of research supporting the protocol, aiming to advance patient access to innovative mental health therapies.
Key Highlights
- BrainsWay's SWIFT Accelerated Deep TMS protocol now has favorable coverage for over 70 million lives in the U.S.
- Continued momentum in favorable policy changes for Deep TMS for major depressive disorder (MDD) and obsessive-compulsive disorder (OCD).
- CEO Hadar Levy highlights increasing adoption pathways for SWIFT due to strong efficacy data and publications.
- BrainsWay leads in noninvasive neurostimulation with proprietary H-coil technology and clinical research.
Price Impact
More from BWAY